Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson's disease
Authors:
- Klaus P WandingerKWKlaus P Wandinger
- Johann M HagenahJHJohann M Hagenah
- Harald KlüterHKHarald Klüter
- Matthias RothermundtMRMatthias Rothermundt
- Marion PetersMPMarion Peters
- Peter ViereggePVPeter Vieregge
- 1 August 1999
- journal article
- clinical trial
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 98 (2) , 214-220
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brainJournal of Neural Transmission, 1996
- Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's diseaseNeuroscience Letters, 1996
- The IL-2/IL-2 receptor system: A current overviewCell, 1993
- TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional PropertiesAnnual Review of Immunology, 1989
- Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigensClinical Immunology and Immunopathology, 1989
- Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetesClinical Immunology and Immunopathology, 1988
- Acquired Defect in Interleukin-2 Production in Patients with Type I Diabetes MellitusNew England Journal of Medicine, 1986
- Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitusDiabetes, 1984
- A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a InfectionNew England Journal of Medicine, 1982
- ParkinsonismNeurology, 1967